skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Intracoronary brachytherapy following drug-eluting stent failure It's still not time to hang up the spikes{exclamation_point}

Abstract

Drug-eluting stents (DES) have significantly reduced the incidence of restenosis. Although the results obtained with these novel antiproliferative devices are encouraging, recent reports have shown that DES are not completely immune from restenosis. Therefore, the broad use of DES has inevitably led to a major issue: treatment of DES failure. Intracoronary brachytherapy (IBT) represents an important advancement for treatment of in-stent restenosis (ISR) and has led to important pathophysiological insight on the restenotic process. To date, IBT, when properly used, still represents the gold standard for treatment of ISR. However, experience with IBT is for treatment of ISR occurring with bare metal stents (BMS). Whether IBT may be used with the same safety and efficacy profile as an adjunctive treatment for ISR following DES implantation is still unknown. In this article, we report the outcome of a series of patients with DES failure treated with IBT. IBT for treatment of DES failure was shown to be both safe and efficient and, therefore, until ISR exists, IBT still remains an important player in this growing and even more challenging setting.

Authors:
; ; ; ; ; ; ; ; ; ;
Publication Date:
OSTI Identifier:
20650567
Resource Type:
Journal Article
Journal Name:
Cardiovascular Radiation Medicine
Additional Journal Information:
Journal Volume: 4; Journal Issue: 4; Other Information: DOI: 10.1016/j.carrad.2004.02.003; PII: S1522186504000095; Copyright (c) 2004 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 1522-1865
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; BRACHYTHERAPY; DRUGS; FAILURES; PATIENTS; SAFETY STANDARDS

Citation Formats

Angiolillo, Dominick J, Sabate, Manel, Jimenez-Quevedo, Pilar, Alfonso, Fernando, Galvan, Carmen, Fernandez, Jose Miguel, Hernandez-Antolin, Rosana, Escaned, Javier, Banuelos, Camino, Moreno, Raul, and Macaya, Carlos. Intracoronary brachytherapy following drug-eluting stent failure It's still not time to hang up the spikes{exclamation_point}. United States: N. p., 2003. Web. doi:10.1016/j.carrad.2004.02.003.
Angiolillo, Dominick J, Sabate, Manel, Jimenez-Quevedo, Pilar, Alfonso, Fernando, Galvan, Carmen, Fernandez, Jose Miguel, Hernandez-Antolin, Rosana, Escaned, Javier, Banuelos, Camino, Moreno, Raul, & Macaya, Carlos. Intracoronary brachytherapy following drug-eluting stent failure It's still not time to hang up the spikes{exclamation_point}. United States. https://doi.org/10.1016/j.carrad.2004.02.003
Angiolillo, Dominick J, Sabate, Manel, Jimenez-Quevedo, Pilar, Alfonso, Fernando, Galvan, Carmen, Fernandez, Jose Miguel, Hernandez-Antolin, Rosana, Escaned, Javier, Banuelos, Camino, Moreno, Raul, and Macaya, Carlos. 2003. "Intracoronary brachytherapy following drug-eluting stent failure It's still not time to hang up the spikes{exclamation_point}". United States. https://doi.org/10.1016/j.carrad.2004.02.003.
@article{osti_20650567,
title = {Intracoronary brachytherapy following drug-eluting stent failure It's still not time to hang up the spikes{exclamation_point}},
author = {Angiolillo, Dominick J and Sabate, Manel and Jimenez-Quevedo, Pilar and Alfonso, Fernando and Galvan, Carmen and Fernandez, Jose Miguel and Hernandez-Antolin, Rosana and Escaned, Javier and Banuelos, Camino and Moreno, Raul and Macaya, Carlos},
abstractNote = {Drug-eluting stents (DES) have significantly reduced the incidence of restenosis. Although the results obtained with these novel antiproliferative devices are encouraging, recent reports have shown that DES are not completely immune from restenosis. Therefore, the broad use of DES has inevitably led to a major issue: treatment of DES failure. Intracoronary brachytherapy (IBT) represents an important advancement for treatment of in-stent restenosis (ISR) and has led to important pathophysiological insight on the restenotic process. To date, IBT, when properly used, still represents the gold standard for treatment of ISR. However, experience with IBT is for treatment of ISR occurring with bare metal stents (BMS). Whether IBT may be used with the same safety and efficacy profile as an adjunctive treatment for ISR following DES implantation is still unknown. In this article, we report the outcome of a series of patients with DES failure treated with IBT. IBT for treatment of DES failure was shown to be both safe and efficient and, therefore, until ISR exists, IBT still remains an important player in this growing and even more challenging setting.},
doi = {10.1016/j.carrad.2004.02.003},
url = {https://www.osti.gov/biblio/20650567}, journal = {Cardiovascular Radiation Medicine},
issn = {1522-1865},
number = 4,
volume = 4,
place = {United States},
year = {Mon Dec 01 00:00:00 EST 2003},
month = {Mon Dec 01 00:00:00 EST 2003}
}